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ABSTRACT
Purpose Postoperative atrial fibrillation (POAF) is a 
potentially lethal and morbid complication after open heart 
surgery. This systematic review and meta- analysis aimed 
to investigate metoprolol compared with other treatments 
for prophylaxis against POAF.
Methods We searched CENTRAL, MEDLINE, EMBASE 
and trial registries for randomised controlled trials that 
evaluated metoprolol for preventing the occurrence of 
POAF after surgery against other treatments or placebo. 
Random- effects model was used for estimating the risk 
ratios (RRs) and mean differences with 95% CIs.
Results Nine trials involving 1570 patients showed 
metoprolol reduced POAF compared with placebo (416 
patients; RR 0.46, 95% CI 0.33 to 0.66; I²=21%; risk 
difference (RD) –0.19, 95% CI –0.28 to –0.10). However, 
metoprolol increased the risk of POAF compared with 
carvedilol (159 patients; RR 1.59, 95% CI 1.20 to 2.12; 
I²=4%; RD 0.13, 95% CI 0.06 to 0.20). There was no 
difference when compared with sotalol or amiodarone. 
The occurrence of cardiovascular conditions after drugs 
administration or death between the groups was not 
different. The overall quality of evidence was moderate 
to high. Subgroup analysis and funnel plot were not 
performed.
Conclusions Metoprolol is effective in preventing POAF 
compared with placebo and showed no difference with 
class III antiarrhythmic drugs. Death and thromboembolism 
are associated with open heart surgery, but not significant 
in relation to the use of metoprolol.
PROSPERO registration number CRD42019131585.
INTRODUCTION
Postoperative atrial fibrillation (POAF) is 
the most important type of secondary AF, 
representing a new- onset AF in the imme-
diate period after cardiac surgery.1 POAF is 
a potentially lethal and morbid complication 
after open heart surgery; it is reported that 
POAF occurs in 20%–40% of cardiac- related 
surgery and 10%–20% of non- cardiac opera-
tions.1 This complication is characterised by 
episodes that are often brief, asymptomatic 
and paroxysmal, usually peaking between 
the second and fourth days postoperatively. 
Patients undergoing concomitant valvular 
heart surgery have a higher incidence of AF, 
which may reach 64%.2
The POAF is usually self- limiting in patients 
with no prior history of AF, resolving sponta-
neously without any interventions.3 Although 
seen as a temporary problem related to 
cardiac surgery, POAF can lead to morbidity 
and mortality in high- risk patients.4 The devel-
opment of POAF is associated with increased 
risk of thrombotic events, such as stroke, 
thrombophlebitis, myocardial infarction and 
prolonged hospital stay. It is estimated that 
this problem will continue to grow, given that 
the patient population undergoing cardiac 
surgery is ageing, and the incidence of POAF 
is largely age dependent.4
The aetiology of POAF is multifactorial 
and contributed to by certain factors, such as 
systemic and local inflammation and oxida-
tive stress, as well as electrolyte imbalance.5 AF 
in the postoperative period is due to ectopic 
firing or re- entry. This occurs because of the 
presence of an atrial substrate produced by 
the postoperative remodelling process after 
cardiac surgery.1 Pharmacological agents that 
have been extensively used in POAF prophy-
laxis are beta- blockers and amiodarone, while 
non- pharmacological agents include atrial 
pacing. Currently, there are no definitive 
Strengths and limitations of this study
 ► Meta- analysis of randomised controlled trials.
 ► Cochrane methodology.
 ► Grading of Recommendations Assessment, 
Development and Evaluation quality assessments.
 ► Subgroup analysis was not performed.
 ► Funnel plot was not performed.
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preventive strategies for AF following heart surgery.6 
There were a few meta- analyses for the evaluation of 
metoprolol for prophylaxis of POAF7 8; following which, 
new trials were included in this review. The aim of this 
review is to investigate metoprolol in comparison with 
control for prophylaxis against POAF in order to reduce 
the occurrence of adverse events in the postoperative 
period, such as death and cardioembolic events. We 
hypothesised that metoprolol is effective for prophylaxis 
against POAF compared with other treatment options.
MATERIALS AND METHODS
The methodology and reporting were based on recom-
mendations from the Cochrane Collaboration9 and 
the Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses statement10; the evaluation was 
conducted according to the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) 
guidelines.11
Eligibility criteria
We considered randomised controlled trials (RCTs) 
comparing metoprolol with placebo (or no treatment) 
or other drugs that are commonly used in POAF prophy-
laxis. We included blinded and open- label studies. The 
intervention was intravenous or oral metoprolol used 
perioperatively, during hospitalisation, for preventing 
the occurrence of POAF after surgery. The comparisons 
included placebo or other drugs commonly used for the 
prevention of POAF. We considered for inclusion trials 
that included patients who underwent cardiac surgery 
(both revascularisation and valve surgery) without prior 
or concomitant AF. There were no restrictions on age or 
other comorbidities, such as hypertension and diabetes. 
We only considered publications that were published in 
the English language.
Search strategy
We searched the Cochrane Central Register of Controlled 
Trials (CENTRAL 2019, Issue 3), MEDLINE, EMBASE 
and trial registries (till March 2019). The searches for 
systematic reviews aim to be as extensive as possible to 
ensure that the review includes as many of the necessary 
and relevant studies as possible. However, when devel-
oping a search strategy, a balance must be struck between 
striving for comprehensiveness or sensitivity and main-
taining relevance or precision. Increasing a search’s sensi-
tivity will reduce its precision, and more non- relevant 
articles will be retrieved.9 We have combined the concepts 
of population, intervention and study design based on 
the text words ‘metoprolol’, ‘beta blocker’ and ‘AF’ and 
Boolean operators like AND, OR, truncation and wild-
cards for variations in words to have a balance in the sensi-
tivity and precision of the search strategy. We checked the 
reference list of the identified RCTs and review articles 
to find unpublished trials or trials not identified by the 
electronic searches. We also searched for ongoing trials 
through WHO International Clinical Trials Registry Plat-
form (ICTRP) and  ClinicalTrials. gov.
Trial selection
Two review authors (MNN and ZMA) scanned the titles 
and abstracts independently from the searches and 
obtained full- text articles when they appeared to meet the 
eligibility criteria, or there was insufficient information 
to assess eligibility. We independently assessed the eligi-
bility of the trials and documented the reasons for exclu-
sion. We resolved any disagreements between the review 
authors by discussion. We contacted the trial authors if 
clarification was needed.
Data extraction
Using the data extraction form, the review authors (MNN, 
ZMA) independently extracted the characteristics of the 
trials (study setting), participants’ characteristics (age, 
sex, ethnicity, comorbidities), methodology (number 
of participants randomised and analysed, duration of 
follow- up), description of the intervention (dosage, route 
of administration) and outcomes. When information was 
missing or inadequately reported, we tried to contact the 
corresponding authors for the trial.
The predefined primary outcome was the occurrence of 
a first POAF. The primary outcome refers to the number 
of patients having POAF during the postoperative period 
as diagnosed by a physician on ECG. The ECG moni-
toring was either performed as continuous monitoring or 
when a patient had palpitation or screened in the ward in 
the postoperative period. The secondary outcomes were 
the occurrence of adverse events (stroke, the occurrence 
of hypotension as reported by the clinicians and brady-
cardia after administration of drugs and death during the 
postoperative period).
Assessment of risk of bias
We assessed the risk of bias based on random sequence 
generation, allocation concealment, blinding of partic-
ipants and personnel, blinding of outcome assessors, 
completeness of outcome data, the selectivity of outcome 
reporting and other bias, as discussed in the Cochrane 
Handbook for Systematic Reviews of Interventions.9 We 
categorised the risk of bias as low, unclear or high.
Statistical analysis
All the statistical analyses were performed using Review 
Manager (RevMan) V.5.3.5 (Nordic Cochrane Centre, 
Cochrane Collaboration). For all the included trials 
with categorical outcomes, we calculated the risk ratios 
(RRs), risk difference (RD) and 95% CIs, and for numer-
ical outcomes, we calculated the mean differences and 
95% CIs. If data from two or more trials were included 
in an analysis of an outcome, we reported the results of 
random- effects model.
We assessed the presence of heterogeneity via two steps. 
First, we assessed obvious heterogeneity at face value 
by comparing populations, settings, interventions and 
outcomes. Second, we assessed statistical heterogeneity by 
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means of the I² statistic: 0%–40%, may not be important; 
30%–60%, may represent moderate heterogeneity; 
50%–90%, may represent substantial heterogeneity and 
75%–100%, represents considerable heterogeneity.9
If possible, we conducted subgroup analyses on patient 
age, comorbidities and the mode of drug administration. 
We performed a sensitivity analysis for investigating the 
effect of risk of bias for sequence generation and alloca-
tion concealment of the included studies.
Grading quality of evidence
We used the principles of the GRADE approach for eval-
uating the quality of evidence in systematic reviews.11 
This approach specifies four levels of quality, the highest 
of which is for randomised trial evidence. It can be 
downgraded to moderate, low or even very low- quality 
evidence, depending on the presence of the following 
four factors: (1) limitations in the design and implemen-
tation of available studies, (2) indirectness of evidence, 
(3) unexplained heterogeneity or inconsistency of results 
and (4) imprecision of results. We used the GRADEpro 
GDT software (Evidence Prime) for reflecting the quality 
of evidence for each individual outcome, and the assess-
ment was phased in together with the summary of find-
ings table.
Patients and public involvement
Patients and the public were not involved in the design or 
planning of the study.
RESULTS
Trial selection
We retrieved 122 records from the search of the electronic 
databases and 8 records from other sources (figure 1). 
We screened 86 records, excluded 71 records that obvi-
ously did not fulfil the eligibility criteria based on the title 
and abstract and reviewed the full texts of 15 studies. We 
identified nine articles as meeting the review inclusion 
criteria, while six were not eligible for inclusion. Two 
trials were excluded because they were not conducted on 
heart surgery patients,12 13 three because they included 
unsuitable comparators14–16; one was on dose- dependent 
effect of metoprolol.17 There were no ongoing trials 
found during the search process.
Characteristics of trials
We included nine trials with a total of 1570 participants. 
All the trials contributed to the primary outcome. Four 
trials related to the secondary outcomes, which were the 
occurrence of death and stroke18 19 and occurrence of 
bradycardia and hypotension.20 21 Table 1 summarises the 
characteristics of the included trials.
Participants
Eight6 18–20 22–25 of the nine included trials were conducted 
in high- income countries in Europe, while one was from a 
South American country.21 All the trials were from a single 
centre except one that involved three cardiac centres 
in Finland.18 The trials were conducted in patients that 
underwent cardiac surgery, including coronary artery 
bypass surgery and valvular heart surgery. In all the trials, 
patients were excluded if they had a history of arrhythmia.
Interventions
Three trials were compared against placebo or no treat-
ment,20 21 24 four against carvedilol,6 22 23 25 two against 
amiodarone18 19 and two against sotalol.20 24 The routes of 
administration for metoprolol were oral,6 19–23 25 intrave-
nous18 and both oral and intravenous24 and the range of 
doses given per day was 100–200 mg. Sotalol, amiodarone 
and carvedilol were given in the same fashion, and the 
doses were titrated based on the patients’ heart rates and 
Figure 1 Flow chart of the selected studies.
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tolerance levels. The drugs were given preoperatively 
in some studies, and some were given in the immediate 
postoperative period or in the morning post- operatively. 
The drugs were continued in the postoperative period in 
the intensive care unit (ICU) or postoperative ward. The 
patients were then monitored on continuous ECG moni-
toring with a time ranging from 2 days to until discharge.
Outcomes
All the trials reported the occurrence of AF in the post-
operative period with continuous ECG monitoring in 
the ICU and in the ward. POAF was reported as the first 
occurrence of AF in the postoperative period; however, 
the period of monitoring was not consistent throughout 
the trials. It ranges from immediately after surgery until 7 
days postoperation or discharge from hospital. Three trials 
reported the results of metoprolol versus placebo.20 21 24 
Two trials involved comparisons with sotalol,20 24 two with 
amiodarone18 19 and four with carvedilol.6 22 23 25
Assessment of risk of bias
The assessment of risk of bias is shown in figures 2 and 
3. Figure 2 shows the proportion of studies assessed as 
having low, high or unclear risk of bias for each risk of 
bias indicator. Figure 3 shows the risk of bias indicators 
for individual studies. All the trials described the method 
of randomisation for participant allocation except 
one.24 Six trials applied the simple randomisation tech-
nique.6 19 21–23 25 One trial used block randomisation,18 and 
another used a randomisation table.20 Allocation conceal-
ment was not mentioned in five trials,6 22–25 and conceal-
ment was not performed in two trials.19 21 Only two trials 
mentioned their method of concealment, where conceal-
ment was designated via envelopes opened in sequence18 
and concealment by means of opaque capsules.20 Two 
trials did not mention blinding of participants,21 24 
while two trials were open- labelled trials.18 19 Four trials 
employed participant blinding.6 20 22 23
All the trials reported the outcomes as specified in their 
objectives. Owing to the short follow- up periods in the 
studies, none of the trials had lost to follow- up. Two trials 
mentioned that they performed an intention- to- treat anal-
ysis.20 21 The other trials did not mention the intention 
to treat principle analysis, but the participants were anal-
ysed according to the groups to which they were initially 
assigned.6 18 19 22–25 All nine trials reported the outcomes 
as specified in their methods.6 18–25 None of the trials were 
registered in the WHO ICTRP or  ClinicalTrials. gov. We 
detected no other potential sources of bias.
Clinical outcomes
The primary outcome, that is, the occurrence of a first 
POAF was measured in all the trials. The secondary 
outcomes (stroke, hypotension, bradycardia and death) 
were only measured in four trials,18–21 which limits our 
analysis of the secondary outcomes to comparisons 
between the amiodarone and placebo groups only.
Postoperative atrial fibrillation
In the metoprolol versus placebo comparison, three trials 
reported the occurrence of POAF.20 21 24 There was signif-
icant reduction in POAF (416 patients; RR 0.46, 95% CI 
0.33 to 0.66; I²=0%; RD –0.19, 95% CI –0.28 to –0.10; p 
<0.001) (figure 4). The GRADE quality assessment for 
this outcome was moderate (table 2).
In the metoprolol versus carvedilol comparison, four 
trials reported the occurrence of POAF6 22 23 25 (587 
patients; RR 1.59, 95% CI 1.20 to 2.12; I²=4%; RD 0.13, 
95% CI 0.06 to 0.20; p=0.001) (figure 5). In this compar-
ison, the dose of metoprolol ranged between 50 and 200 
mg per day, and carvedilol ranged between 12.5 and 25 
mg per day. The heterogeneity of the trials was low at 4% 
Figure 2 A graph of the risk of bias according to review authors’ judgements about each risk of bias item presented as 
percentages across all included studies.
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indicating similarities among the trials with regards to 
population, intervention and comparator of the outcome 
tested. We did not perform subgroup analysis according 
to the dosage of drugs due to the limited number of trials, 
and its indication in the presence of high heterogeneity. 
The GRADE quality assessment was high (table 3). In the 
metoprolol versus sotalol comparison, two trials reported 
the occurrence of POAF20 24 (205 patients; RR 1.79, 95% 
CI 0.24 to 13.52; p=0.570; I²=73%) (see online supple-
mental figure 1). The GRADE quality assessment was low 
(table 4). In the metoprolol versus amiodarone compar-
ison, two trials reported the occurrence of POAF18 19 (567 
patients; RR 0.99, 95% CI 0.71 to 1.39; p=0.960; I²=0%) 
(see online supplemental figure 2). The GRADE quality 
assessment was high (table 5).
Stroke
Stroke as a secondary outcome was reported for the 
metoprolol versus amiodarone comparison, and two trials 
reported the occurrence of stroke18 19 (567 patients; RR 
1.45, 95% CI 0.50 to 4.16; p=0.490; I²=0%) (see online 
supplemental figure 3). The GRADE quality assessment 
was moderate (table 5).
Hypotension
Hypotension as a secondary outcome was reported for 
the metoprolol versus placebo comparison, and two trials 
reported the occurrence of hypotension after adminis-
tration of drugs20 21 (327 patients; RR 1.40, 95% CI 0.03 
to 56.55; p=0.180; I²=68%) (see online supplemental 
figure 4). The GRADE quality assessment was moderate 
(table 2).
Bradycardia
Bradycardia as a secondary outcome was reported for the 
metoprolol versus placebo comparison, and two trials 
reported the occurrence of bradycardia after drug admin-
istration20 21 (327 patients; RR 2.28, 95% CI 0.91 to 6.22; 
p=0.080; I²=0%) (see online supplemental figure 5). The 
GRADE quality assessment was moderate (table 2).
Death
This secondary outcome was reported for the metoprolol 
versus amiodarone comparison, and two trials reported 
the occurrence of death18 19 (567 patients; RR=0.96, 95% 
CI 0.20 to 4.70; p =0.960; I²=0%) (see online supplemental 
figure 6). The GRADE quality assessment was moderate 
(table 5).
Subgroup and sensitivity analysis
The intended subgroup analyses for outcomes with 
high heterogeneity was not performed due to the 
limited number of trials. For sensitivity analyses, there 
Figure 3 A summary of the risk of bias according to review 
authors’ judgements about each risk of bias item for each 
included study.
Figure 4 Individual and pooled effect size (risk ratio) of postoperative atrial fibrillation treated with metoprolol against placebo 
or no treatment. M- H, Mantel- Haenszel.
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was no substantial change in the effect sizes or CI of all 
the outcomes with an unclear risk of bias for allocation 
concealment and random sequence generation.
DISCUSSION
This review was designed to include all RCTs that focused 
on the effectiveness of metoprolol on the occurrence of 
POAF in heart surgery patients. The nine identified trials 
addressed several comparisons of drugs and outcomes 
with specified objectives. Metoprolol significantly 
reduced POAF compared with placebo, and there were 
no differences in the occurrence of side effects, which 
were hypotension and bradycardia in the two groups. 
In the metoprolol versus carvedilol comparison, metop-
rolol increased the risk of POAF compared with carve-
dilol. There was no difference compared with sotalol or 
amiodarone in the occurrence of POAF. For the metopr-
olol versus amiodarone group, there was no difference in 
the occurrence of stroke and death.
We performed a comprehensive and extensive litera-
ture review for assessing the effectiveness of metoprolol 
on the occurrence of POAF in heart surgery patients. We 
included nine trials that focused on patients undergoing 
revascularisation surgery and valvular heart surgery. The 
intervention group in each trial took metoprolol, and the 
control groups ranged from placebo to carvedilol, sotalol 
and amiodarone. The time of drug administration and 
doses given to the patients were different in each trial, 
thereby limiting the applicability of the findings in this 
review. We tried to use subgroup analysis to assess the 
dosage, routes of administration and the time at which the 
treatment was initiated, but there were limited number of 
Table 2 The grade quality assessment for metoprolol versus placebo or non- treatment group
Metoprolol compared with placebo or non- treatment for postoperative atrial fibrillation prophylaxis
Patient or population: cardiac surgery
Intervention: metoprolol
Comparison: placebo or non- treatment
Outcomes























Assumed risk calculated 
from the mean risk across 
the control groups
358 per 1000 165 per 1000
(115 to 236)







Assumed risk calculated 
from the mean risk across 
the control groups
12 per 1000 21 per 1000
(5 to 87)







Assumed risk calculated 
from the mean risk across 
the control groups
30 per 1000 77 per 1000
(30 to 200)
GRADE Working Group grades of evidence.
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate 
of effect.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).
GRADE, grading of recommendations assessment, development and evaluation; RCTs, randomised controlled trials; RR, risk ratio.
Figure 5 Individual and pooled effect size (risk ratio) of postoperative atrial fibrillation treated with metoprolol compared with 
carvedilol. M- H, Mantel- Haenszel.
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trials to enable to do so. We cannot determine whether 
earlier or prolonged administration of the drugs would 
affect the occurrence of POAF. Few trials included the 
adverse effects of surgeries, which limited the process of 
examining the efficacy and safety of the drugs used.
We found that the quality of evidence in the trials for 
the primary outcome was variable; mainly ranging from 
moderate to high. Although there were unclear and high 
risk of bias in some risk of bias assessments, we think that 
these risks are not significant for the review. All these trials 
had a short follow- up in the acute phase, with an objective 
assessment that was unlikely to affect the outcome. For most 
of our meta- analyses, we encountered little heterogeneity 
among the participants. We tried to reduce publication 
bias by checking the reference lists of all related studies for 
further references and searching multiple databases, but 
we restricted the search to English language publications 
due to the language barrier. Despite the vigorous search of 
journal databases, we cannot be sure that we have extracted 
all trials relevant to our review.
Table 3 The grade quality assessment for metoprolol versus carvedilol
Metoprolol compared with carvedilol for postoperative atrial fibrillation prophylaxis


























calculated from the 
mean risk across 
the control groups
207 per 1000 334 per 1000
(253 to 442)
GRADE Working Group grades of evidence.
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate 
of effect.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).
GRADE, grading of recommendations assessment, development and evaluation; RCTs, randomised controlled trials; RR, risk ratio.
Table 4 The grade quality assessment for metoprolol versus sotalol
Metoprolol compared with sotalol for postoperative atrial fibrillation prophylaxis

























calculated from the 
mean risk across 
the control groups
202 per 1000 216 per 1000
(129 to 363)
GRADE Working Group grades of evidence.
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate 
of effect.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).
GRADE, grading of recommendations assessment, development and evaluation; RCTs, randomised controlled trials; RR, risk ratio.
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The use of beta- blockers significantly reduces the 
POAF rate in cardiac surgery patients.1 From the results 
of our review, we found that metoprolol significantly 
reduced POAF after cardiac surgery compared with the 
placebo, but it was not superior to carvedilol, sotalol 
or amiodarone. However, the comparison with sotalol 
has low quality of evidence and was limited by the small 
number of samples. One meta- analysis found that carve-
dilol is better than metoprolol in reducing POAF after 
cardiac surgery,7 and one review agreed that carvedilol 
is superior to metoprolol in this regard.8 A meta- analysis 
reported a greater than 30% risk reduction with sotalol 
compared with other beta- blockers, including metop-
rolol.26 A physician or cardiothoracic surgeon should 
be aware of the various beta- blockers available in their 
clinical practice. The selection should be based on the 
evidence available; for example, studies showed that 
carvedilol is still superior but in cases when it is not avail-
able, then other beta- blockers would be of choice.
CONCLUSIONS
In this study, metoprolol was found to be effective 
compared with placebo and showed no difference with 
class III antiarrhythmic drugs. Side effects, such as hypo-
tension and bradycardia, was not found to be significant 
in this study; thus, we can say that metoprolol is relatively 
safe for POAF prophylaxis.
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Table 5 The grade quality assessment for metoprolol versus amiodarone
Metoprolol compared with amiodarone for postoperative atrial fibrillation prophylaxis



























Assumed risk calculated 
from the mean risk across 
the control groups
190 per 1000 188 per 1000
(135 to 264)







Assumed risk calculated 
from the mean risk across 
the control groups
18 per 1000 26 per 1000
(9 to 75)







Assumed risk calculated 
from the mean risk across 
the control groups
Eleven per 1000 Ten per 1000
(2 to 51)
GRADE Working Group grades of evidence.
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate 
of effect.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).
GRADE, grading of recommendations assessment, development and evaluation; RCTs, randomised controlled trials; RR, risk ratio.
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